Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CRISTINA IVAN and ANIL K SOOD.
CRISTINA IVAN
Connection Strength
7.526
ANIL K SOOD
  1. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol. 2013 Mar; 128(3):506-11.
    View in: PubMed
    Score: 0.433
  2. Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L. Nat Commun. 2023 04 26; 14(1):2407.
    View in: PubMed
    Score: 0.223
  3. Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer. Cancers (Basel). 2022 Mar 15; 14(6).
    View in: PubMed
    Score: 0.206
  4. Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Mol Cancer Ther. 2021 12; 20(12):2352-2361.
    View in: PubMed
    Score: 0.200
  5. MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. Gynecol Oncol. 2021 10; 163(1):181-190.
    View in: PubMed
    Score: 0.198
  6. Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling. Mol Cancer Res. 2021 11; 19(11):1917-1928.
    View in: PubMed
    Score: 0.198
  7. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2021 04 01; 131(7).
    View in: PubMed
    Score: 0.193
  8. Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. Cell Rep. 2021 02 09; 34(6):108726.
    View in: PubMed
    Score: 0.191
  9. The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene. 2021 01; 40(2):384-395.
    View in: PubMed
    Score: 0.188
  10. Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. Oncotarget. 2020 Jul 21; 11(29):2819-2833.
    View in: PubMed
    Score: 0.184
  11. Author Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 2020 06 03; 11(1):2867.
    View in: PubMed
    Score: 0.182
  12. Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene. 2019 08; 38(33):6095-6108.
    View in: PubMed
    Score: 0.171
  13. Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. Mol Cancer Ther. 2019 02; 18(2):421-436.
    View in: PubMed
    Score: 0.164
  14. PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Mol Cancer Ther. 2019 01; 18(1):162-172.
    View in: PubMed
    Score: 0.163
  15. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun. 2018 07 26; 9(1):2923.
    View in: PubMed
    Score: 0.160
  16. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2018 07 02; 128(7):3199.
    View in: PubMed
    Score: 0.159
  17. ADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget. 2018 May 18; 9(38):25115-25126.
    View in: PubMed
    Score: 0.158
  18. Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Front Oncol. 2018; 8:9.
    View in: PubMed
    Score: 0.155
  19. Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther. 2018 02; 17(2):464-473.
    View in: PubMed
    Score: 0.154
  20. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun. 2017 08 21; 8(1):310.
    View in: PubMed
    Score: 0.150
  21. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight. 2017 Aug 17; 2(16).
    View in: PubMed
    Score: 0.150
  22. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. J Natl Cancer Inst. 2017 07 01; 109(7).
    View in: PubMed
    Score: 0.149
  23. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight. 2016 Oct 20; 1(17):e87754.
    View in: PubMed
    Score: 0.142
  24. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat Commun. 2016 Apr 04; 7:11169.
    View in: PubMed
    Score: 0.137
  25. Role of Increased n-acetylaspartate Levels in Cancer. J Natl Cancer Inst. 2016 Jan 26; 108(6):djv426.
    View in: PubMed
    Score: 0.135
  26. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Rep. 2015 Dec 22; 13(11):2395-2402.
    View in: PubMed
    Score: 0.134
  27. Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. Clin Cancer Res. 2016 Apr 01; 22(7):1713-24.
    View in: PubMed
    Score: 0.133
  28. PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Mol Cancer Ther. 2015 Jun; 14(6):1466-1475.
    View in: PubMed
    Score: 0.127
  29. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. Clin Cancer Res. 2015 Jan 15; 21(2):448-59.
    View in: PubMed
    Score: 0.124
  30. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 2014 Oct 29; 5:5202.
    View in: PubMed
    Score: 0.124
  31. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res. 2014 Jun 15; 20(12):3280-8.
    View in: PubMed
    Score: 0.119
  32. Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93.
    View in: PubMed
    Score: 0.119
  33. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun. 2014 Mar 12; 5:3459.
    View in: PubMed
    Score: 0.118
  34. Autocrine effects of tumor-derived complement. Cell Rep. 2014 Mar 27; 6(6):1085-1095.
    View in: PubMed
    Score: 0.118
  35. Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6532-43.
    View in: PubMed
    Score: 0.115
  36. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 02; 105(19):1485-95.
    View in: PubMed
    Score: 0.115
  37. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2013 May; 123(5):2119-30.
    View in: PubMed
    Score: 0.111
  38. Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Front Oncol. 2013; 3:58.
    View in: PubMed
    Score: 0.111
  39. Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427.
    View in: PubMed
    Score: 0.109
  40. Corrigendum to Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine. 2024 Dec 04; 111:105486.
    View in: PubMed
    Score: 0.062
  41. Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. Proc Natl Acad Sci U S A. 2014 Apr 08; 111(14):5331-6.
    View in: PubMed
    Score: 0.059
  42. Author Correction: Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discov. 2023 Nov 08; 9(1):111.
    View in: PubMed
    Score: 0.058
  43. Corrigendum to "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis" [EBioMedicine 40 (2019) 290-304]. EBioMedicine. 2022 Sep; 83:104194.
    View in: PubMed
    Score: 0.053
  44. CORRIGENDUM: GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal. 2022 Jan; 89:110147.
    View in: PubMed
    Score: 0.050
  45. Author Correction: TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 2021 Sep; 597(7875):E6.
    View in: PubMed
    Score: 0.050
  46. Conversion of RNA Aptamer into Modified DNA Aptamers Provides for Prolonged Stability and Enhanced Antitumor Activity. J Am Chem Soc. 2021 05 26; 143(20):7655-7670.
    View in: PubMed
    Score: 0.049
  47. PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway. Int J Mol Sci. 2021 Feb 13; 22(4).
    View in: PubMed
    Score: 0.048
  48. Corrigendum to 'Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer' [EBioMedicine 38 (2018) 100-112]. EBioMedicine. 2020 Feb; 52:102630.
    View in: PubMed
    Score: 0.044
  49. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal. 2020 04; 68:109539.
    View in: PubMed
    Score: 0.044
  50. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. EBioMedicine. 2019 Feb; 40:290-304.
    View in: PubMed
    Score: 0.041
  51. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine. 2018 Dec; 38:100-112.
    View in: PubMed
    Score: 0.041
  52. EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis. Oncogene. 2019 03; 38(12):2123-2134.
    View in: PubMed
    Score: 0.041
  53. A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nat Commun. 2018 01 31; 9(1):461.
    View in: PubMed
    Score: 0.039
  54. Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discov. 2017; 3:17029.
    View in: PubMed
    Score: 0.038
  55. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Mol Ther Nucleic Acids. 2017 Dec 15; 9:251-262.
    View in: PubMed
    Score: 0.037
  56. Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget. 2017 Mar 21; 8(12):20145-20164.
    View in: PubMed
    Score: 0.037
  57. Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clin Cancer Res. 2017 06 01; 23(11):2891-2904.
    View in: PubMed
    Score: 0.036
  58. Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. Cancer Res. 2016 12 15; 76(24):7194-7207.
    View in: PubMed
    Score: 0.035
  59. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):15093-104.
    View in: PubMed
    Score: 0.034
  60. A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. Mol Syst Biol. 2015 Dec 11; 11(12):842.
    View in: PubMed
    Score: 0.033
  61. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. 2015 Oct 06; 6(30):29161-77.
    View in: PubMed
    Score: 0.033
  62. Targeting c-MYC in Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2015 Oct; 14(10):2260-9.
    View in: PubMed
    Score: 0.033
  63. The ZNF304-integrin axis protects against anoikis in cancer. Nat Commun. 2015 Jun 17; 6:7351.
    View in: PubMed
    Score: 0.032
  64. Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis. Cell Cycle. 2015; 14(14):2265-73.
    View in: PubMed
    Score: 0.032
  65. TP53 loss creates therapeutic vulnerability in?colorectal cancer. Nature. 2015 Apr 30; 520(7549):697-701.
    View in: PubMed
    Score: 0.032
  66. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat Cell Biol. 2015 Mar; 17(3):311-21.
    View in: PubMed
    Score: 0.032
  67. Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clin Cancer Res. 2015 May 01; 21(9):2127-37.
    View in: PubMed
    Score: 0.031
  68. Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat Commun. 2014 Oct 29; 5:5203.
    View in: PubMed
    Score: 0.031
  69. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2014 Nov; 13(11):2583-94.
    View in: PubMed
    Score: 0.031
  70. The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression. Cell Rep. 2014 Sep 11; 8(5):1447-60.
    View in: PubMed
    Score: 0.031
  71. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013 Nov; 3(11):1302-15.
    View in: PubMed
    Score: 0.029
  72. p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation. Cell Cycle. 2012 Sep 15; 11(18):3433-42.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.